AmbioPharm announced June 16 a $118.96 million expansion of its Aiken County, South Carolina headquarters, adding a 68,000-square-foot modular manufacturing building at its existing 1024 Dittman Court campus in North Augusta and creating more than 200 new jobs. The facility will offer commercial-scale GMP synthesis including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid approaches, mirroring upgrades made to AmbioPharm's Shanghai facility. Operations target end of 2027. The announcement arrives roughly three weeks after the May 27, 2026 close of CordenPharma's acquisition of AmbioPharm, which secured CordenPharma a second US peptide site (joining Boulder, Colorado) and its first Shanghai-based supply node. AmbioPharm shareholders are reinvesting in the combined entity. The expansion is the largest single US peptide-manufacturing capacity addition of 2026 to date.
PolyPeptide Group AG announced that it has expanded its existing credit facility to EUR 200 million in support of growth ambitions and progress toward doubling 2023 revenue by 2028. The Swedish-Belgian peptide CDMO is one of the four large dedicated peptide manufacturers — alongside Bachem, CordenPharma, and Sun Pharma's Hyderabad PolyPeptide platform — and has previously announced a EUR 100M expansion in Malmö plus large-scale SPPS production in Braine-l'Alleud, Belgium that started in late 2024. The credit move heads into TIDES USA 2026 (May 11–14, Boston), where capacity, GMP investment, and large-scale SPPS economics will dominate the panel agenda.
CordenPharma's Boulder, Colorado expansion is now confirmed at $500 million, with the first phase coming online in 2026 and full completion in 2028. The site will add new large-scale manufacturing lines and a greenfield facility that more than doubles its solid-phase peptide synthesis (SPPS) capacity to over 42,000 liters by 2028 — positioning Boulder among the largest peptide production sites worldwide. CordenPharma Colorado leased 64,000 square feet at BioMed Realty's Flatiron Park 5505 Central — Boulder's first purpose-built speculative lab building — and will add more than 200 employees to the existing 700-person workforce. The expansion sits within CordenPharma's broader €900M+ ($1B+) global peptide platform investment that also includes a >€500M greenfield site near Basel.